← Browse by Condition
Medical Condition

waldenstrom macroglobulinemia

Total Trials
4
Recruiting Now
4
Trial Phases
Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for waldenstrom macroglobulinemia sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — waldenstrom macroglobulinemia Clinical Trials

How many clinical trials are currently recruiting for waldenstrom macroglobulinemia?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for waldenstrom macroglobulinemia, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for waldenstrom macroglobulinemia?
waldenstrom macroglobulinemia research spans Phase 1 (2 trials), Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a waldenstrom macroglobulinemia clinical trial?
Eligibility criteria for waldenstrom macroglobulinemia trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
2
Phase 2
1
Top Sponsors
Newave Pharmaceutical Inc 1 trial
Christian Buske 1 trial
Mayo Clinic 1 trial
Schrödinger, Inc. 1 trial

Recruiting Clinical Trials

NCT04775745 Phase 1
Recruiting
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Enrollment
60 pts
Location
United States
Sponsor
Newave Pharmaceutical Inc
View Trial →
NCT05099471 Phase 2
Recruiting
Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia
Enrollment
80 pts
Location
Germany, Greece
Sponsor
Christian Buske
View Trial →
NCT06151730
Recruiting
Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
Enrollment
100 pts
Location
United States
Sponsor
Mayo Clinic
View Trial →
NCT05544019 Phase 1
Recruiting
Study of SGR-1505 in Mature B-Cell Neoplasms
Enrollment
98 pts
Location
United States, Franc...
Sponsor
Schrödinger, Inc.
View Trial →

Related Conditions

mantle cell lymphoma (3) follicular lymphoma (2) marginal zone lymphoma (2) chronic lymphocytic leukemia (2) cll sll (1) diffuse large b cell lymphoma (1) hairy cell leukemia (1) treatment naive (1) hematopoietic and lymphoid system neoplasm (1) mature b cell neoplasm (1) non hodgkin lymphoma (1) dlbcl (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology